Mitomycin
- PDF / 169,929 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 27 Downloads / 159 Views
1 S
Hypocalcaemia: case report A 69-year-old woman developed hypocalcaemia following treatment with mitomycin for carcinomatosis. The woman was admitted to the hospital for elective cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin for her carcinomatosis. Her medical history was significant for vitamin-D deficiency, colon cancer stage-III, hemicolectomy, and she had received FOLFOX regimen, and FOLFIRI chemotherapy regimen with cetuximab. Upon admission, she underwent cytoreductive surgery, followed by closed abdomen HIPEC with mitomycin [mitomycin-C; dose not stated] at 40–42°C. Thereafter, she developed acute muscle spasms, tetany and episodes of repetitive hyperflexion of legs and arms during the first night after the chemotherapy. No apparent loss of sensibility was noted upon neurological examination and her laboratory tests showed mild hypomagnesaemia [aetiology not stated] and significant hypocalcaemia. Further laboratory investigations showed that the Hb, sodium, chloride, potassium, phosphorus levels and renal functions were within normal limits. The woman was treated with calcium gluconate and magnesium. Her calcium level improved; however, it still remained low. She was also found to have developed hypoparathyroidism [aetiology not stated]. Eventually, her calcium level normalised and neuromuscular excitability also resolved. It was considered that the hypocalcaemia was secondary to mitomycin [duration of treatment to reaction onset not stated]. Tharmalingam S, et al. Severe Hypocalcemia and Transient Hypoparathyroidism after Hyperthermic Intraperitoneal Chemotherapy. Hormone and Metabolic Research 52: 803516019 689-690, No. 9, 2020. Available from: URL: http://doi.org/10.1055/a-1220-6971
0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Nov 2020 No. 1831
Data Loading...
